Today

Agents

Chat

Arena

Discover

More

App

FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's - BIIB News | Rallies

FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's

BIIB•2026-07-13

FDA approves new starting dosage regimen

FDA approves new starting dosage regimen for Leqembi subcutaneous formulation for Alzheimer's disease treatment.

Related News

Walmart must face gay ex-worker's harassment claim, US court rules

WMT•2026-07-13

Talos Energy unit issues USD 800 million 8% second-priority secured notes due 2034 under new indenture

TALO•2026-07-13

Glenfarne Announces a $500 Million Investment in Texas LNG by HPS Investment Partners

BLK•2026-07-13

L3Harris gets $955 million US contract to supply 18 satellites for Golden Dome missile shield

LHX•2026-07-13